Share-Based Payments (Tables)

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Share-based Compensation Awards and Valuation Details

A summary of the awards and valuation details:

Awarded to	Terms	Valuation	Recognition and Presentation
Total Shareholder Return Units (TSRUs)(a), (b)
Senior and other key management and select employees	•Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the five or seven-year term, if and to the extent the total value is positive. •Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant. •Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant.	As of the grant date using a Monte Carlo simulation model	Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
Restricted Stock Units (RSUs)
Select employees	•Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs. •For RSUs granted, in virtually all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date.	As of the grant date using the closing price of our common stock	Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
Portfolio Performance Shares (PPSs)
Select employees	•Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares. •For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s long-term product portfolio during a three or five-year performance period from the year of the grant date, as applicable. •The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.	As of the grant date using the intrinsic value method using the closing price of our common stock	Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management’s assessment of the probability that the specified performance criteria will be achieved.
Performance Share Awards (PSAs)
Senior and other key management	•Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures: a.Adjusted net income over three one-year periods; and b.TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the three-year performance period. •PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. •The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.	As of the grant date using the intrinsic value method using the closing price of our common stock	Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved.
Breakthrough Performance Awards (BPAs)
Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)	•Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares. •For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the one-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer’s product pipeline during the performance period. •The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.	As of the grant date using the intrinsic value method using the closing price of our common stock	Amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved and/or management’s assessment of the probable vesting term.

Awarded to	Terms	Valuation	Recognition and Presentation
Stock Options
Select employees	•Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested. •Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented. •Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years.	As of the grant date using the Black-Scholes-Merton option-pricing model	Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.

(a)Retirement-eligible holders, as defined in the grant terms, can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs’ original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.

(b)In 2017, Performance Total Shareholder Return Units (PTSRUs) were awarded to the Former Chairman and Chief Executive Officer (1,444,395 PTSRUs) and 361,099 PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President Pfizer Innovative Health) at a grant price of $30.31 and at a GDFV of $5.54 per PTSRU. In addition to having the same characteristics and valuation methodology of TSRUs, PTSRU grants require special service and performance conditions.

Schedule of Share-based Payment Arrangement Activity

The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:
(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION)	TSRUs			RSUs			PPSs			PSAs			Stock Options
Year Ended December 31,	2021	2020	2019	2021	2020	2019	2021	2020	2019	2021	2020	2019	2021	2020	2019
Total fair value of shares vested(a)	$7.26	$6.22	$8.52	$304	$334	$454	$181	$119	$136	$33	$25	$64	$4.86	$3.56	$5.98
Total intrinsic value of options exercised or share units converted	$594	$84	$175				$228	$224	$245				$584	$293	$261
Cash received upon exercise													$795	$425	$394
Tax benefits realized from exercise													$106	$55	$47
Compensation cost recognized, pre-tax(b)	$259	$287	$294	$281	$272	$275	$535	$180	$114	$76	$31	$28	$5	$6	$7
Total compensation cost related to nonvested awards not yet recognized, pre-tax	$187	$224	$229	$271	$228	$241	$175	$104	$87	$54	$32	$34	$3	$4	$5
Weighted-average period over which cost is expected to be recognized (years)	1.6	1.6	1.6	1.8	1.7	1.7	1.8	1.8	1.8	1.8	1.9	1.8	1.6	1.7	1.6

(a)Weighted-average GDFV per TSRUs and stock options.

(b)TSRU includes expense for PTSRUs, which is not significant for all years presented.

Summary of all TSRU, RSU, PPS, PSA and BPA activity during 2021 (with the shares granted representing the maximum award that could be achieved for PPSs, PSAs and BPAs):
	TSRUs					RSUs			PPSs(a)			PSAs			BPAs
	TSRUs	Per TSRU, Weighted Average				Shares	Weighted Avg. GDFV per share		Shares	Weighted Avg. Intrinsic Value per share		Shares	Weighted Avg. Intrinsic Value per share		Shares	Weighted Avg. Intrinsic Value per share
	(Thousands)	GDFV		Grant Price		(Thousands)			(Thousands)			(Thousands)			(Thousands)
Nonvested, December 31, 2020	129,844	$	6.90	$	32.94	23,692	$	35.50	20,077	$	36.81	5,264	$	36.81	—	$	—
Granted	34,522	7.26		33.83		10,893	34.31		8,632	33.82		1,798	33.82		1,165	38.73
Vested	(44,888)	7.21		30.54		(8,747)	34.66		(6,095)	33.88		(984)	33.85		—	—
Reinvested dividend equivalents						956	41.33
Forfeited	(4,879)	6.77		33.78		(1,255)	35.17		(1,133)	41.45		(924)	34.43		(306)	47.47
Nonvested, December 31, 2021	114,599	$	6.90	$	34.12	25,540	$	35.52	21,480	$	59.05	5,154	$	59.05	859	$	59.05

(a)Vested and non-vested shares outstanding, but not paid as of December 31, 2021 were 34.1 million.

Summary of TSRU and PTU information as of December 31, 2021(a), (b):
	TSRUs (Thousands)	PTUs (Thousands)	Weighted-Average Grant Price Per TSRU		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (Millions)
TSRUs Outstanding	206,996	—	$	31.71	2.2	$	5,969
TSRUs Vested	92,398	—	28.72		0.8	2,946
TSRUs Expected to vest(c)	110,476	—	34.16		3.3	2,910
TSRUs exercised and converted to PTUs	—	3,074	$	—	0.8	$	182

(a)In 2021, we settled 46,060,346 TSRUs with a weighted-average grant price of $23.04 per unit.

(b)In 2021, 7,093,787 TSRUs with a weighted-average grant price of $27.41 per unit were converted into 2,943,737 PTUs.

(c)The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.

Schedule of Valuation Assumptions

Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:
	TSRUs						Stock Options
Year Ended December 31,	2021		2020		2019		2021		2020		2019
Expected dividend yield (based on a constant dividend yield during the expected term)	4.51	%	4.36	%	3.27	%	4.51	%	4.36	%	3.27	%
Risk-free interest rate (based on interpolated yield on U.S. Treasury zero-coupon issues)	0.93	%	1.15	%	2.55	%	1.27	%	1.25	%	2.66	%
Expected stock price volatility (based on implied volatility, after consideration of historical volatility)	26.53	%	20.99	%	18.34	%	26.54	%	20.97	%	18.34	%
TSRUs contractual/stock options expected term, years (based on historical exercise and post-vesting termination patterns for stock options)	5.15		5.12		5.13		6.75		6.75		6.75

Schedule of Share-based Compensation, Stock Options, Activity

Summary of all stock option activity during 2021:
	Shares (Thousands)	Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value(a) (Millions)
Outstanding, December 31, 2020	75,402	$	28.31
Granted	779	33.82
Exercised	(31,036)	25.75
Forfeited	(89)	34.39
Expired	(181)	20.27
Outstanding, December 31, 2021	44,874	30.20		2.7	$	1,295
Vested and expected to vest, December 31, 2021(b)	44,747	30.19		2.7	1,291
Exercisable, December 31, 2021	41,583	$	29.81	2.3	$	1,216

(a)Market price of our underlying common stock less exercise price.

(b)The number of options expected to vest takes into account an estimate of expected forfeitures.